Table 5. Multivariate analysis of prognostic factors in LA NPC patients.
| Characteristic | HR | 95% CI | P-value | |
|---|---|---|---|---|
| OS | CC regimen of cisplatin vs. non-cisplatin | 0.256 | 0.074–0.886 | 0.031 |
| III vs. IV* | 0.291 | 0.113–0.754 | 0.011 | |
| PFS | III vs. IV* | 0.438 | 0.213–0.899 | 0.024 |
| CR vs. non-CR | 0.441 | 0.210–0.926 | 0.031 | |
| LRFS | — | — | — | — |
| RRFS | CR vs. non-CR | 0.300 | 0.091–0.994 | 0.049 |
| With vs. without AC | 0.222 | 0.047–1.043 | 0.057 | |
| DMFS | CC regimen of cisplatin vs. non-cisplatin | 0.207 | 0.058–0.734 | 0.015 |
| III vs. IV* | 0.166 | 0.047–0.583 | 0.005 |
Abbreviations: OS: overall survival. PFS: progression-free survival. LRFS: local recurrence-free survival. RRFS: regional recurrence-free survival. DMFS: distant metastasis-free survival. CC: concurrent chemotherapy. AC: adjuvant chemotherapy.
*The 7th AJCC/UICC staging system.